T
Tim Moors
Researcher at VU University Medical Center
Publications - 17
Citations - 1286
Tim Moors is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Parkinson's disease & Alpha-synuclein. The author has an hindex of 7, co-authored 13 publications receiving 782 citations. Previous affiliations of Tim Moors include VU University Amsterdam & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes.
Sarah H Shahmoradian,Sarah H Shahmoradian,Amanda J Lewis,Christel Genoud,Jürgen Hench,Tim Moors,Paula P Navarro,Daniel Castaño-Díez,Gabriel Schweighauser,Alexandra Graff-Meyer,Kenneth N. Goldie,Rosmarie Sütterlin,Evelien Huisman,Angela Ingrassia,Yvonne de Gier,Annemieke J.M. Rozemuller,Jing Wang,Anne De Paepe,Johannes Erny,Andreas Staempfli,Joerg Hoernschemeyer,Frederik Großerüschkamp,Daniel Niedieker,Samir F. El-Mashtoly,Marialuisa Quadri,Wilfred F. J. van IJcken,Vincenzo Bonifati,Klaus Gerwert,Bernd Bohrmann,Stephan Frank,Markus Britschgi,Henning Stahlberg,Wilma D.J. van de Berg,Matthias E. Lauer +33 more
TL;DR: Using three-dimensional correlative light and electron microscopy of Lewy bodies and Lewy neurites in postmortem brains of Parkinson’s disease patients, researchers show that the major constituents are membranes rather than proteinaceous filaments.
Journal ArticleDOI
Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients
Karlijn J. Doorn,Karlijn J. Doorn,Tim Moors,Benjamin Drukarch,Wilma D.J. van de Berg,Paul J. Lucassen,Anne-Marie van Dam +6 more
TL;DR: The regional changes in microglial phenotype andTLR2 expression in primed/reactive microglia in the SN and HC of iLBD cases indicate that TLR2 may play a prominent role in the microglian-mediated responses that could be important for PD progression.
Journal ArticleDOI
Therapeutic potential of autophagy-enhancing agents in Parkinson's disease
Tim Moors,Jeroen J.M. Hoozemans,Angela Ingrassia,Tommaso Beccari,Lucilla Parnetti,Marie-Christine Chartier-Harlin,Marie-Christine Chartier-Harlin,Wilma D.J. van de Berg +7 more
TL;DR: The targeted manipulation of downstream ALP components, rather than broad autophagy stimulation, may be an attractive strategy for the development of novel pharmacological therapies in PD.
Journal ArticleDOI
Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links
Tim Moors,Silvia Paciotti,Davide Chiasserini,Paolo Calabresi,Lucilla Parnetti,Tommaso Beccari,Wilma D.J. van de Berg +6 more
TL;DR: The combination of CSF lysosomal markers with α‐synuclein species and indicators of mitochondrial dysfunction, inflammation, and other pathological proteins in PD may be able to facilitate a more accurate diagnosis of PD.
Journal ArticleDOI
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies.
Tim Moors,Silvia Paciotti,Angela Ingrassia,Marialuisa Quadri,Guido J. Breedveld,Anna Tasegian,Davide Chiasserini,Paolo Eusebi,Gonzalo Duran-Pacheco,Thomas Kremer,Paolo Calabresi,Vincenzo Bonifati,Lucilla Parnetti,Tommaso Beccari,Wilma D.J. van de Berg +14 more
TL;DR: Findings of this study confirm findings from previous studies, suggesting a role for GCase in GBA-associated as well as sporadic PD and DLB patients, and show decreased GCase activity in brains of PD andDLB patients with and without GBA variants.